Skip to main content
Sign In

Pharmacology PhD Program

Cardiovascular & Pulmonary Biology

Cardiovascular Biology 

Information to come.

Associated Faculty

M.D./Ph.D., 1998, Univ. of Washington
Targeting the glucocorticoid receptor for the treatment of inflammatory disorders of the lung such as asthma.
Tim McKinsey 
Associate Professor
Ph.D., 1998, Vanderbilt Univ.
Epigenetic regulation of heart failure; signaling and transcriptional mechanisms of muscle disease.
David Port 
Ph.D., 1989, Univ. of Utah
G-protein linked receptors and their regulation; regulation of mRNA stability.
Catherine Proenza 
Assistant Professor
Ph.D., 1999, Colorado State Univ.
We are interested in the cellular and molecular machinery responsible for cardiac pacemaking and its regulation by the autonomic nervous system.
Kunhua Song 
Assistant Professor
Ph.D., 2007, Univ. of Texas Southwestern Medical Center
Using stem cells as a tool in the treatment of heart disease.
Carmen Sucharov 
Assistant Professor
Ph.D., 1997, Univ. of Pennsylvania/ Univ. Federal do Rio de Janerio
Signal transduction and gene expression in adult and pediatric human heart failure.
University Distinguished Professor and Vice Chancellor for Research
Ph.D., 1971, Johns Hopkins Univ.
Neuroscience, cerebrovascular physiology, stroke, cardiac arrest/CPR, respiration, cardiopulmonary physiology.
M.D., 1979, São Paulo University of Medicine
Overall goals are to define the mechanisms of COPD pathogenesis and the molecular, cellular, and histopathological features of Pulmonary Hypertension. Our lab studies the pathogenesis of cigarette smoke induced emphysema and its underlying mechanisms, including the role of RTP-801 and adipocytokine, as well as his investigation in the pathogenesis of schistosomiasis-related pulmonary hypertension and development of targeted methods and treatment of pulmonary hypertension.
Mary Weiser-Evans 
Associate Professor
Ph.D., 1992, Colorado State Univ.
Defining the molecular signaling mechanisms regulating vascular smooth muscle cell function in the setting of vascular fibroproliferative diseases, including restenosis and pulmonary hypertension.


David Port, Program Director
Email: David Port, Ph.D.
Shanelle Felder, Program Administrator
Voice: 303-724-3565 | Fax: 303-724-3663 |
12800 E. 19th Avenue, Mail Stop 8303, Research Complex 1 North Tower, Room 6106, Aurora, CO 80045

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.